{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:00:33Z","timestamp":1784286033480,"version":"3.55.0"},"reference-count":93,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/ftd.0b013e31826d07ea","type":"journal-article","created":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T07:58:33Z","timestamp":1349423913000},"page":"607-614","source":"Crossref","is-referenced-by-count":21,"title":["Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome"],"prefix":"10.1097","volume":"34","author":[{"given":"Heli","family":"Malm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.infbeh.2010.09.008","article-title":"Prenatal depression effects on early development: a review.","volume":"34","author":"Field","year":"2011","journal-title":"Infant Behav Dev"},{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/archgenpsychiatry.2011.2333","article-title":". Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.","volume":"69","author":"El Marroun","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/humrep\/den342","article-title":"Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study.","volume":"24","author":"Li Li","year":"2009","journal-title":"Hum Reprod"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1176\/appi.ajp.2008.08081170","article-title":". Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.","volume":"166","author":"Wisner","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajog.2007.07.036","article-title":". Use of antidepressant medications during pregnancy: a multisite study.","volume":"198","author":"Andrade","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/JCP.0b013e3182490eaf","article-title":". Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study.","volume":"32","author":"Nordeng","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/AOG.0b013e318220edcc","article-title":". Selective serotonin reuptake inhibitors and risk for major congenital anomalies.","volume":"118","author":"Malm","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdra.20641","article-title":". First trimester use of paroxetine and congenital heart defects: a population based case-control study.","volume":"88","author":"Bakker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.reprotox.2010.04.015","article-title":"Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs).","volume":"30","author":"Ellfolk","year":"2010","journal-title":"Reprod Toxicol"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1017\/S0033291709992194","article-title":"Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.","volume":"40","author":"Reis","year":"2010","journal-title":"Psychol Med"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/070674370905400405","article-title":". Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study.","volume":"54","author":"Einarson","year":"2009","journal-title":"Can J Psychiatry"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bdra.20627","article-title":". First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies.","volume":"88","author":"Wurst","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/bdra.20615","article-title":". Are selective serotonin reuptake inhibitors cardiac teratogens Echocardiographic screening of newborns with persistent heart murmur.","volume":"85","author":"Merlob","year":"2009","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"B3569","DOI":"10.1136\/bmj.b3569","article-title":". Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study.","volume":"339","author":"Pedersen","year":"2009","journal-title":"BMJ"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4065\/84.1.23","article-title":". Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy.","volume":"84","author":"Wichman","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2008.03261.x","article-title":". Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.","volume":"66","author":"Diav-Citrin","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.2007.07060879","article-title":". Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy.","volume":"165","author":"Einarson","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/bdrb.20144","article-title":". Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.","volume":"83","author":"Oberlander","year":"2008","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1056\/NEJMoa066584","article-title":"; National Birth defects Prevention study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.","volume":"356","author":"Alwan","year":"2007","journal-title":"N Engl J Med"},{"key":"R21-1-20210129","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2007.05.003","article-title":". Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors.","volume":"29","author":"Bar-Oz","year":"2007","journal-title":"Clin Ther"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/bdrb.20099","article-title":". First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.","volume":"80","author":"Berard","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/pds.1463","article-title":". Paroxetine in the first trimester and the prevalence of congenital malformations.","volume":"16","author":"Cole","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/pds.1462","article-title":". Risks of congenital malformations and perinatal events among infants exposed to antidepressant medication during pregnancy.","volume":"16","author":"Davis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/bdra.20327","article-title":"Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.","volume":"79","author":"Kallen","year":"2007","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMoa067407","article-title":". First trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.","volume":"356","author":"Louik","year":"2007","journal-title":"N Engl J Med"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.ede.0000239581.76793.ae","article-title":". Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations.","volume":"17","author":"Wogelius","year":"2006","journal-title":"Epidemiology"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.AOG.0000187302.61812.53","article-title":"Risks associated with selective serotonin reuptake inhibitors in pregnancy.","volume":"106","author":"Malm","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ajog.2005.05.012","article-title":". Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome.","volume":"193","author":"Sivojelezova","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s002280050664","article-title":"Delivery outcome after the use of antidepressants in early pregnancy.","volume":"55","author":"Ericson","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.279.8.609","article-title":". Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.","volume":"279","author":"Kulin","year":"1998","journal-title":"JAMA"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0029-7844(97)00070-7","article-title":"Effects of first-trimester fluoxetine exposure on the newborn.","volume":"89","author":"Goldstein","year":"1997","journal-title":"Obstet Gynecol"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM199610033351402","article-title":". Birth outcomes in pregnant women taking fluoxetine.","volume":"335","author":"Chambers","year":"1996","journal-title":"N Engl J Med"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1001\/jama.1993.03500170076037","article-title":". Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac).","volume":"269","author":"Pastuszak","year":"1993","journal-title":"JAMA"},{"key":"R35-1-20210129","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archpediatrics.2009.164","article-title":"Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.","volume":"163","author":"Lund","year":"2009","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e3181bf344c","article-title":". Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction.","volume":"29","author":"Toh","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1192\/bjp.bp.107.037101","article-title":". Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study.","volume":"192","author":"Oberlander","year":"2008","journal-title":"Br J Psychiatry"},{"key":"R38-1-20210129","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/archpsyc.63.8.898","article-title":". Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.","volume":"63","author":"Oberlander","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R39-1-20210129","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajog.2006.02.019","article-title":". Selective serotonin reuptake inhibitors and adverse pregnancy outcomes.","volume":"194","author":"Wen","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R40-1-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archpedi.158.4.312","article-title":"Neonate characteristics after maternal use of antidepressants in late pregnancy.","volume":"158","author":"Kallen","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R41-1-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00737-004-0057-5","article-title":". The impact of depression and fluoxetine treatment on obstetrical outcome.","volume":"7","author":"Suri","year":"2004","journal-title":"Arch Womens Ment Health"},{"key":"R42-1-20210129","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archpedi.156.11.1129","article-title":". Perinatal outcome following third trimester exposure to paroxetine.","volume":"156","author":"Costei","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R43-1-20210129","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1176\/appi.ajp.159.12.2055","article-title":"Outcomes of prenatal antidepressant exposure.","volume":"159","author":"Simon","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R44-1-20210129","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.reprotox.2011.09.004","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations.","volume":"32","author":"Sadler","year":"2011","journal-title":"Reprod Toxicol"},{"key":"R45-1-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/YCO.0b013e3283503680","article-title":"Anxiety, depression and stress in pregnancy: implications for mothers, children, research, and practice.","volume":"25","author":"Dunkel Schetter","year":"2012","journal-title":"Curr Opin Psychiatry"},{"key":"R46-1-20210129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/jwh.2009.1387","article-title":". Maternal and fetal outcomes among women with depression.","volume":"19","author":"Bansil","year":"2010","journal-title":"J Womens Health (Larchmt)"},{"key":"R47-1-20210129","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1001\/jama.293.19.2372","article-title":". Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.","volume":"293","author":"Moses-Kolko","year":"2005","journal-title":"JAMA"},{"key":"R48-1-20210129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3928\/00904481-20080301-02","article-title":"Poor neonatal adaptation in term infant. Fluoxetine toxicity.","volume":"37","author":"Kwon","year":"2008","journal-title":"Pediatr Ann"},{"key":"R49-1-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.ftd.0000187971.95000.25","article-title":". Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels.","volume":"28","author":"Knoppert","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R50-1-20210129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S1701-2163(16)34157-3","article-title":". Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretoninnorepinephrine reuptake inhibitors.","volume":"31","author":"Koren","year":"2009","journal-title":"J Obstet Gynaecol Can"},{"key":"R51-1-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.ftd.0000187972.02624.2e","article-title":". Citalopram serum and milk levels in mother and infant during lactation.","volume":"28","author":"Franssen","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R52-1-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ftd.0000187973.02624.67","article-title":"A new indication for therapeutic drug monitoring in the neonate.","volume":"28","author":"Koren","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R53-1-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","article-title":". Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.","volume":"160","author":"Levinson-Castiel","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R54-1-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajog.2012.02.009","article-title":"Antidepressant use during pregnancy: the benefit-risk ratio.","volume":"207","author":"Koren","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R55-1-20210129","doi-asserted-by":"crossref","first-page":"D8012","DOI":"10.1136\/bmj.d8012","article-title":". Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries.","volume":"344","author":"Kieler","year":"2012","journal-title":"BMJ"},{"key":"R56-1-20210129","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/pds.1570","article-title":"Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn.","volume":"17","author":"Kallen","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R57-1-20210129","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMoa052744","article-title":". Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.","volume":"354","author":"Chambers","year":"2006","journal-title":"N Engl J Med"},{"key":"R58-1-20210129","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.reprotox.2012.04.015","article-title":"Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review.","volume":"34","author":"t Jong","year":"2012","journal-title":"Reprod Toxicol"},{"key":"R59-1-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00213-011-2270-z","article-title":". Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.","volume":"217","author":"Casper","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R60-1-20210129","first-page":"E66","article-title":"Adverse effects in neonates exposed to SSRIs and SNRI in late gestationMotherisk Update 2008.","volume":"16","author":"Koren","year":"2009","journal-title":"Can J Clin Pharmacol"},{"key":"R61-1-20210129","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(05)17865-9","article-title":". Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis.","volume":"365","author":"Sanz","year":"2005","journal-title":"Lancet"},{"key":"R62-1-20210129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.jp.7211352","article-title":". Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis.","volume":"25","author":"Lattimore","year":"2005","journal-title":"J Perinatol"},{"key":"R63-1-20210129","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/00048670903107583","article-title":". Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study.","volume":"43","author":"Galbally","year":"2009","journal-title":"Aust N Z J Psychiatry"},{"key":"R64-1-20210129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0028-1103296","article-title":". Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.","volume":"42","author":"Rampono","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"R65-1-20210129","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e318173aa2e","article-title":"A new look at the neonates clinical presentation after in utero exposure to antidepressants in late pregnancy.","volume":"28","author":"Boucher","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R66-1-20210129","first-page":"554","article-title":"Clarke P, et al..","volume":"19","author":"Haddad","year":"2005","journal-title":"Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome J Psychopharmacol"},{"key":"R67-1-20210129","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/archpsyc.60.7.720","article-title":". Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactinconcentrations.","volume":"60","author":"Laine","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R68-1-20210129","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00007691-200412000-00016","article-title":"Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy.","volume":"26","author":"Laine","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R69-1-20210129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.euroneuro.2009.01.006","article-title":". MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs.","volume":"19","author":"Hilli","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"R70-1-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.mp.4002007","article-title":". Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.","volume":"13","author":"Oberlander","year":"2008","journal-title":"Mol Psychiatry"},{"key":"R71-1-20210129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-0447.2009.01490.x","article-title":"A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health.","volume":"121","author":"Warburton","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"R72-1-20210129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1176\/appi.ajp.2011.11040553","article-title":"Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies.","volume":"169","author":"Occhiogrosso","year":"2012","journal-title":"Am J Psychiatry"},{"key":"R73-1-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0030-1262507","article-title":". Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors.","volume":"28","author":"Wilson","year":"2011","journal-title":"Am J Perinatol"},{"key":"R74-1-20210129","doi-asserted-by":"crossref","first-page":"E272","DOI":"10.1542\/peds.2006-3037","article-title":". Risk factors for persistent pulmonary hypertension of the newborn.","volume":"120","author":"Hernandez-Diaz","year":"2007","journal-title":"Pediatrics"},{"key":"R75-1-20210129","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/pds.1710","article-title":". Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn.","volume":"18","author":"Andrade","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R76-1-20210129","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1164\/rccm.200701-163OC","article-title":". Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.","volume":"176","author":"Fornaro","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R77-1-20210129","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.earlhumdev.2012.01.004","article-title":". Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure.","volume":"88","author":"Lim","year":"2012","journal-title":"Early Hum Dev"},{"key":"R78-1-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tips.2009.11.003","article-title":"New perspectives on the neurodevelopmental effects of SSRIs.","volume":"31","author":"Homberg","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"R79-1-20210129","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/clpt.2009.201","article-title":"Neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence.","volume":"86","author":"Oberlander","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R80-1-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1523\/JNEUROSCI.3973-07.2008","article-title":"Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice.","volume":"28","author":"Ansorge","year":"2008","journal-title":"J Neurosci"},{"key":"R81-1-20210129","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1126\/science.1101678","article-title":". Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice.","volume":"306","author":"Ansorge","year":"2004","journal-title":"Science"},{"key":"R82-1-20210129","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nrn1256","article-title":"The developmental role of serotonin: news from mouse molecular genetics.","volume":"4","author":"Gaspar","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"R83-1-20210129","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.neuropharm.2011.09.015","article-title":". Prenatal fluoxetine exposure induces life-long serotonin 5-HT receptor-dependent cortical abnormalities and anxiety-like behaviour.","volume":"62","author":"Smit-Rigter","year":"2012","journal-title":"Neuropharmacology"},{"key":"R84-1-20210129","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.biopsych.2003.09.003","article-title":"Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression.","volume":"54","author":"Holmes","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R85-1-20210129","first-page":"880","article-title":"Serotonin, pregnancy and increased autism prevalence: is there a link Med Hypotheses.","volume":"74","author":"Hadjikhani","year":"2010","journal-title":""},{"key":"R86-1-20210129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.clp.2009.06.002","article-title":". Fetal effects of psychoactive drugs.","volume":"36","author":"Salisbury","year":"2009","journal-title":"Clin Perinatol"},{"key":"R87-1-20210129","first-page":"245","article-title":"Glover V; Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health.","volume":"48","author":"Talge","year":"2007","journal-title":"Antenatal maternal stress and long-term effects on child neurodevelopment: how and why J Child Psychol Psychiatry"},{"key":"R88-1-20210129","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/jp.2010.211","article-title":". Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome.","volume":"31","author":"Klinger","year":"2011","journal-title":"J Perinatol"},{"key":"R89-1-20210129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJM199701233360404","article-title":". Neurodevelopment of children exposed in utero to antidepressant drugs.","volume":"336","author":"Nulman","year":"1997","journal-title":"N Engl J Med"},{"key":"R90-1-20210129","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1176\/appi.ajp.159.11.1889","article-title":". Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study.","volume":"159","author":"Nulman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R91-1-20210129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mcp.2002.126181","article-title":". Citalopram in pregnancy and lactation.","volume":"72","author":"Heikkinen","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R92-1-20210129","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archgenpsychiatry.2011.73","article-title":". Antidepressant use during pregnancy and childhood autism spectrum disorders.","volume":"68","author":"Croen","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"R93-1-20210129","doi-asserted-by":"crossref","first-page":"D7642","DOI":"10.1136\/bmj.d7642","article-title":"SSRIs and persistent pulmonary hypertension of the newborn.","volume":"344","author":"Koren","year":"2012","journal-title":"BMJ"},{"key":"R94-1-20210129","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/AOG.0b013e31823a577b","article-title":". Selective serotonin reuptake inhibitors and risk for major congenital anomalies (author reply).","volume":"118","author":"Malm","year":"2011","journal-title":"Obstet Gynecol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31826d07ea","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T01:25:03Z","timestamp":1714440303000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201212000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31826d07ea","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}